Breast Cancer Coverage from Every Angle
Advertisement
Advertisement

Recent News

NCRI Conference: Ongoing Study of Blood Test for Early Detection of Breast Cancer
KEYNOTE-119 Trial of Pembrolizumab Versus Chemotherapy for Triple-Negative Breast Cancer
Pembrolizumab Plus Chemotherapy in Triple-Negative Breast Cancer
FDA Grants Priority Review for Trastuzumab Deruxtecan in Metastatic Breast Cancer
FDA Recommends Warnings on Labeling for Breast Implants
ESMO 2019: Adding Veliparib to Chemotherapy for BRCA-Mutated Breast Cancer
ASCO Breakthrough 2019: Genetic Predictors of Breast Cancer Recurrence After Radiation Therapy
ESMO 2019: Survival Benefit Reported With CDK4/6 Inhibitor in Advanced Breast Cancer
Higher Exposure to Toxic Metals May Equal Higher Breast Cancer Risk
Can Artificial Intelligence Improve Accuracy of Digital Breast Tomosynthesis?
ESMO 2019: Improved Overall Survival With Abemaciclib/Fulvestrant in Advanced Breast Cancer
Quality Care 2019: Web-Based Survey of Patient Engagement Among Breast Cancer Survivors
Quality Care 2019: Chemotherapy Decisions of Older Women With Early-Stage Breast Cancer
Quality Care 2019: Pilot Program Focuses on Improving Breast Cancer Staging Data Entries
ASTRO 2019: Postmastectomy Radiation Therapy for HER2-Positive Breast Cancer
FDA Issues Warning About Lung Inflammation and Use of CDK4/6 Inhibitors
USPSTF Recommendation Updates for Women With BRCA-Related Cancer
Quality Care 2019: Impact of Breast Cancer on Key Support Person’s Employment
Is Red Meat Consumption Linked to Breast Cancer Risk?
Two-Drug Combination Targets Resistance in Cancer
FDA Draft Guidance Encourages Inclusion of Male Patients in Breast Cancer Clinical Trials
Comparing First-Line Treatments in Triple-Negative Breast Cancer
Real-World Data on Palbociclib Plus Endocrine Therapy in Men With Advanced Breast Cancer
IMpassion130 Trial: Atezolizumab Plus Nab-paclitaxel in Advanced Triple-Negative Breast Cancer
Is Soy Intake Related to Bone Fractures for Breast Cancer Survivors?
FDA Requests Manufacturer Recall of Certain Textured Breast Implants
Does Eribulin Mesylate Plus Pembrolizumab Improve Outcomes in Metastatic Breast Cancer?
Communicating With Older Patients About the Need for Breast Cancer Screening
Updated ASCO Clinical Practice Guideline Integrates TAILORx Trial Results in Breast Cancer
NALA Trial: Neratinib Versus Lapatinib Combination Therapy for Metastatic Breast Cancer
De-escalation of Bone-Targeting Agents for Bone Metastases From Breast Cancer
SOPHIA Trial: Adding Margetuximab or Trastuzumab to Chemotherapy in Breast Cancer
Comparing Radiation Regimens in Early-Stage Breast Cancer
Does Environmental Quality Impact the Odds of Developing Aggressive Breast Cancer?
Racial Differences in Risk of Aggressive Breast Cancer After Ductal Carcinoma in Situ
ASCO 2019: Novel Targeted Therapy Active in Metastatic Breast Cancer
ASCO 2019: Final Results of KRISTINE Trial of Neoadjuvant Regimens in HER2-Positive Breast Cancer
New Trastuzumab Biosimilar Approved by the FDA
ASCO 2019: Can Clinical Risk Stratification Predict Chemotherapy Benefit in Early Breast Cancer?
Targeting Mitochondrial Metabolism in Triple-Negative Breast Cancer
ACP Issues New Guidance Statement for Breast Cancer Screening in Average-Risk Women
ASCO 2019: CDK4/6 Inhibitor Plus Endocrine Therapy Improves Overall Survival in Advanced Breast Cancer
Retrospective Update on Nipple-Sparing Mastectomy
U.S. and Canadian Home Recovery Programs After Mastectomy
FDA Approves Alpelisib Combination Therapy for Advanced Breast Cancer
Breast Cancer Treatment Outcomes in Young Women
Effect of Chemotherapy Scheduling on Quality of Life in Advanced Breast Cancer
ARRS 2019: BI-RADS 3 Lesions Identified on High-Risk Screening Breast MRI


By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.